SG11201510654WA - Stable intravenous formulation - Google Patents

Stable intravenous formulation

Info

Publication number
SG11201510654WA
SG11201510654WA SG11201510654WA SG11201510654WA SG11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA
Authority
SG
Singapore
Prior art keywords
intravenous formulation
stable intravenous
stable
formulation
intravenous
Prior art date
Application number
SG11201510654WA
Inventor
Anthony N Galasso
Petra Inbar
Farooq Qureshi
Harendra R Sampat
Shangdong Zhan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201510654WA publication Critical patent/SG11201510654WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11201510654WA 2013-06-24 2014-06-20 Stable intravenous formulation SG11201510654WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838642P 2013-06-24 2013-06-24
US201361840930P 2013-06-28 2013-06-28
PCT/EP2014/062982 WO2014206866A1 (en) 2013-06-24 2014-06-20 Stable intravenous formulation

Publications (1)

Publication Number Publication Date
SG11201510654WA true SG11201510654WA (en) 2016-01-28

Family

ID=51014281

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510654WA SG11201510654WA (en) 2013-06-24 2014-06-20 Stable intravenous formulation

Country Status (15)

Country Link
US (2) US20160136280A1 (en)
EP (1) EP3013316B1 (en)
JP (1) JP6346945B2 (en)
KR (1) KR20160011668A (en)
CN (1) CN105338959A (en)
AR (1) AR096710A1 (en)
AU (1) AU2014301324A1 (en)
BR (1) BR112015029976A2 (en)
CA (1) CA2913174A1 (en)
HK (1) HK1214531A1 (en)
MX (1) MX2015017654A (en)
RU (1) RU2015154097A (en)
SG (1) SG11201510654WA (en)
WO (1) WO2014206866A1 (en)
ZA (1) ZA201508641B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498712B1 (en) * 2016-08-08 2024-01-03 Jiangsu Yayo Biotechnology Co. Ltd Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (en) 2020-08-27 2023-09-20 大塚製薬株式会社 Biomarkers for cancer treatment using MDM2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157491A (en) * 1994-11-30 1996-06-18 Hayashibara Biochem Lab Inc Production of trehalose derivative
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293195A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
JP5490714B2 (en) * 2007-11-28 2014-05-14 メディミューン,エルエルシー Protein preparation
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
EA032840B8 (en) * 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Conjugate-based antifungal prodrugs and use thereof
JP2013018737A (en) * 2011-07-11 2013-01-31 Fujifilm Corp Freeze-dried preparation and method for producing the same
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
US20180071393A1 (en) 2018-03-15
RU2015154097A (en) 2017-07-26
BR112015029976A2 (en) 2017-07-25
CA2913174A1 (en) 2014-12-31
WO2014206866A1 (en) 2014-12-31
US20160136280A1 (en) 2016-05-19
EP3013316B1 (en) 2018-05-30
EP3013316A1 (en) 2016-05-04
AU2014301324A1 (en) 2015-12-10
MX2015017654A (en) 2016-04-15
HK1214531A1 (en) 2016-07-29
JP2016522239A (en) 2016-07-28
KR20160011668A (en) 2016-02-01
AR096710A1 (en) 2016-01-27
JP6346945B2 (en) 2018-06-20
ZA201508641B (en) 2017-09-27
CN105338959A (en) 2016-02-17

Similar Documents

Publication Publication Date Title
EP3065716C0 (en) Formulations
GB201307385D0 (en) Syringes
HRP20180684T1 (en) Drug combination
HK1221790A1 (en) Utility application delivery platform
ZA201506252B (en) Syringe
HK1218076A1 (en) Stabilized pemetrexed formulation
GB201319792D0 (en) Formulations
HK1214951A1 (en) Ophthalimic formulations
GB201320432D0 (en) Novel formulation
ZA201505515B (en) Liquid menthol compositions
PT3060256T (en) A novel stable formulation
HK1214531A1 (en) Stable intravenous formulation
GB201408677D0 (en) Syringes
GB201322948D0 (en) Improved formulation
EP2978473A4 (en) Auto-retractible syringe
HUP1300496A2 (en) Stable pharmaceutical composition
GB2517232B (en) Formulation
GB201317718D0 (en) Novel formulation
IL244316A0 (en) Novel drug formulation
HK1209981A1 (en) Formulation
GB201312347D0 (en) Formulation
GB201317717D0 (en) Novel formulation
GB201320786D0 (en) Medicament
GB201313909D0 (en) Powder formulation
GB201304146D0 (en) Powder formulation